New immunotherapies in Myeloma called CAR T therapy use a patient's own genetically-engineered T cells to attack the tumor. This breakthrough therapy is making its way through the FDA approval process in myeloma and is exciting for myeloma patients. The therapy does have some challenges - because it is customized, it is expensive and complex [...]
This post first appeared on Page Not Found - The Myeloma Crowd, please read the originial post: here
